Analysts Offer Insights on Healthcare Companies: Pfizer (PFE) and Agilent (A)
Analysts fell to the sidelines weighing in on Pfizer (PFE – Research Report) and Agilent (A – Research Report) with neutral ratings, indicating that the experts are neither bullish nor bearish on the stocks.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Pfizer (PFE)
In a report released today, Courtney Breen from Bernstein maintained a Hold rating on Pfizer. The company’s shares closed last Tuesday at $25.72.
According to TipRanks.com, Breen is a 4-star analyst with an average return of
Pfizer has an analyst consensus of Hold, with a price target consensus of $29.17, which is a 15.0% upside from current levels. In a report released today, Berenberg Bank also maintained a Hold rating on the stock with a $25.00 price target.
See Insiders’ Hot Stocks on TipRanks >>
Agilent (A)
Evercore ISI analyst Vijay Kumar maintained a Hold rating on Agilent yesterday and set a price target of $155.00. The company’s shares closed last Tuesday at $157.20.
According to TipRanks.com, Kumar is a 3-star analyst with an average return of
Agilent has an analyst consensus of Moderate Buy, with a price target consensus of $161.54, which is a 7.1% upside from current levels. In a report released yesterday, Barclays also maintained a Hold rating on the stock with a $165.00 price target.
Read More on PFE:
Disclaimer & DisclosureReport an Issue
- Novo Nordisk’s Ozempic and Wegovy Prices Cut 71% under Medicare Plan
- Unusually active option classes on open November 25th
- Notable open interest changes for November 25th
- Pfizer price target raised to $35 from $33 at Guggenheim
- Novo Nordisk Stock (NVO) Under Pressure as Rival Eli Lilly Joins the $1 Trillion Club
